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Abstract
Both pre-clinical and clinical studies indicate that N-acetylcysteine (NAC) may be useful in 
treating relapse to addictive drug use. Cocaine self-administration in rats reduces both cystine-
glutamate exchange and glutamate transport via GLT-1 in the nucleus accumbens, and NAC 
treatment normalizes these two glial processes critical for maintaining glutamate homeostasis. 
However, it is not known if one or both of these actions by NAC is needed to inhibit relapse to 
cocaine seeking. To determine whether the restoration of GLT-1 and/or cystine-glutamate 
exchange is required for NAC to inhibit cue-induced reinstatement of cocaine seeking, we utilized 
the rat self-administration/extinction/reinstatement model of cocaine relapse. Rats were pre-treated 
in the nucleus accumbens with vivo-morpholino anti-sense oligomers targeting either GLT-1 or 
xCT (catalytic subunit of the cystine-glutamate exchanger) overlapping with daily NAC 
administration during extinction (100 mg/kg, i.p. for the last 5 days). Rats then underwent cue-
induced reinstatement of active lever pressing in the absence of NAC, to determine if preventing 
NAC-induced restoration of one or the other protein was sufficient to block the capacity of chronic 
NAC to inhibit reinstatement. The vivo-morpholino suppression of xCT reduced cystine-glutamate 
exchange but did not affect NAC-induced reduction of reinstated cocaine seeking. In contrast, 
suppressing NAC-induced restoration of GLT-1 not only prevented NAC from inhibiting 
reinstatement, but augmented the capacity of cues to reinstate cocaine seeking. We hypothesized 
that the increased reinstatement after inhibiting NAC induction of GLT-1 resulted from increased 
extracellular glutamate, and show that augmented reinstatement is prevented by blocking mGluR5. 
Restoring GLT-1, not cystine-glutamate exchange, is a key mechanism whereby daily NAC 
reduces cue-induced cocaine reinstatement.
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INTRODUCTION
Considerable evidence indicates that chronic cocaine abuse leads to an enduring disruption 
of glutamate homeostasis and glutamatergic signaling within the nucleus accumbens, 
including suppression of both the cystine-glutamate exchanger and high affinity glutamate 
transporters (Kalivas 2009; Wolf & Ferrario 2011). N-acetylcysteine (NAC) is a cystine 
prodrug that activates the cystine-glutamate exchanger (xc−), a key process for maintaining 
extrasynaptic glutamate concentrations (Millea 2009; Lewerenz et al. 2013). Chronic NAC 
reverses chronic cocaine-induced glutamate dysregulation, including normalizing drug-
dependent decreases in extracellular glutamate levels, and protein expression levels of xCT 
(the catalytic subunit of the cystine-glutamate exchanger) and GLT-1 (a high affinity 
astroglial glutamate transporter) (Baker et al. 2003; Knackstedt, Melendez & Kalivas 2010). 
Extensive pre-clinical data supports the therapeutic potential for NAC in addiction and other 
psychiatric conditions (Dean, Giorlando & Berk 2011; Olive et al. 2012), and clinical data 
provides promising findings for treating cocaine and marijuana addiction (Kalivas & 
Volkow 2011; Schmaal et al. 2012; Gray et al. 2012). Hence, understanding the mechanism 
of action of NAC may aid in discovering therapeutic targets for treating addiction.
While it is clear that chronic NAC affects glutamate homeostasis by promoting both cystine-
glutamate exchange and GLT-1, it is not understood whether one or both of these actions is 
required for NAC to inhibit the reinstatement of cocaine seeking. Correspondingly, it is 
unclear whether the putative therapeutic effect of NAC is mediated primarily by its action 
on xCT or GLT-1, or both. Here, we used an antisense vivo-morpholino strategy to inhibit 
the capacity of NAC to induce either cystine-glutamate exchange or GLT-1, and tested 
animals for cocaine seeking 1 day after the last NAC treatment, to isolate a chronic versus 
acute effect. We found that restoring GLT-1, not cystine-glutamate exchange, was critical 
for chronic NAC to inhibit cue-induced reinstatement of cocaine seeking.
MATERIALS AND METHODS
Animal surgeries and behavioral training
Male Sprague Dawley rats (Charles River, 300–350 g; Raleigh, NC, USA) were housed on a 
12-hour reverse-light cycle and provided limited chow (20 g per day) and water ad libitum. 
All animal use practices were per National Institutes of Health guidelines for laboratory 
animal care and were approved by the Medical University of South Carolina Institutional 
Animal Care and Use Committee. For surgical implantation of intrajugular catheters and 
intracranial cannulas, rats were anesthetized with ketamine HCl (100 mg/kg, i.m.) and 
xylazine (7 mg/kg, i.m.). Ketorolac (3 mg/kg, i.p.) was administered before surgery to 
provide analgesia. For catheter implantation, a guide cannula (C313G, Plastics One, 
Roanoke, VA, USA) attached to silastic tubing (.025 ID, .047 OD, Bio-sil; Fisher Scientific, 
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Hampton, New Hampshire) was inserted subcutaneously between the shoulder blades and 
exited the skin via a dermal biopsy hole (3 mm). Catheter exiting the skin was secured by a 
backpack (Instech Laboratories, Plymouth Meeting, PA, USA). The other end of the catheter 
was inserted 3 cm into the right jugular vein and then securely sutured to the underlying 
muscle tissue. Timentin antibiotic (10 mg/0.1 ml, i.v.) was infused at the end of the surgery. 
Prior to onset of self-administration, animals received one 12-hour food training session in 
which an active lever press resulted in the presentation of a chow pellet. Self-administration 
was performed 2 hours per day on a fixed-ratio schedule, in which in response to an active 
lever press, animals received an intravenous infusion of cocaine (0.2 mg per infusion) paired 
with the presentation of light and tone and followed by a 20-second time-out period. 
Criterion for self-administration was a minimum of 10 days in which rats received 10 or 
more daily cocaine infusions. Following self-administration, rats entered extinction training 
during which cocaine and drug-paired cues were no longer delivered in response to an active 
lever press. Only animals who had extinguished to below 65 presses per day at the onset of 
chronic morpholino and NAC treatments were included in the study. During the cue-induced 
reinstatement test, active lever presses were reinforced by the cocaine-associated cues but 
not cocaine.
Vivo-morpholino and NAC treatment protocol
Figure 1a shows the treatment protocol used: rats were treated daily for 3 days with control 
sequence or antisense vivo-morpholino beginning on day 10 of extinction training, and NAC 
(100 mg/kg, i.p.) or saline administered daily for 5 days beginning on day 12 of extinction. 
Control sequence was the exact same order of bases as the antisense, but in reverse sequence 
order. Microinjections of vivo-morpholinos were timed such that protein levels would be 
suppressed during NAC administration and the reinstatement session (Reissner et al. 2012). 
Animals were behaviorally tested or tissue harvested 24 hours after the last injection of 
NAC or saline. During extinction training, rats were micro-injected daily for 3 days with 
vivo-morpholinos 2 hours after the end of each extinction session. Starting on the third day 
of vivo-morpholino microinjection, rats were administered either saline or NAC (100 mg/kg, 
i.p.; Sigma-Aldrich, St. Louis, MO, USA) 2 hours prior to the extinction session. This dose 
and pre-treatment schedule were based on previous studies showing NAC efficacy in 
elevating both cystine-glutamate exchange and GLT-1, and inhibiting reinstated cocaine 
seeking (Knackstedt et al. 2010; Moussawi et al. 2011). NAC was prepared in 27 mg/ml 
NaOH in saline and adjusted to physiological pH, then used immediately. Four more 
extinction sessions were conducted with NAC or saline pre-treatment without vivo-
morpholino pre-treatment. In a final experiment, animals were also pre-treated with saline or 
3-[(2-methyl-4-thiazolyl)ethynyl]pyridine (MTEP; 0.5 mg/kg, i.p.; Tocris Bioscience, 
Minneapolis, MN, USA) 10 minutes prior to beginning a cue-induced reinstatement session. 
This dose of MTEP was based on our previous dose-response indicating that 0.5 mg/kg was 
a maximum dose that would not inhibit cue-induced cocaine reinstatement (Wang et al. 
2013).
Microinjections and histology
The microinjection procedure and vivo-morpholino sequences (Gene Tools, Inc., Philomath, 
OR, USA) were exactly as previously described (Reissner et al. 2012, 2013). All vivo-
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morpholinos were diluted 1:50 in sterile phosphate-buffered saline and a total volume of 1 μl 
was injected per side (30 pmol per injection). A higher dose was used in initial studies; 
because reinstatement for these animals was not significantly different with lower doses, 
data were pooled. Coordinates used for the nucleus accumbens were +1.5 A/P, +1.8 M/L, 
−5.5 D/V, and microinjections were performed 2 mm below the canula base (Paxinos & 
Watson 2005). An antisense vivo-morpholino was constructed for xCT and GLT-1 and 
control sequences for each were the same bases in reverse order. Histology to confirm 
cannula placement was performed following an overdose of pentobarbital and perfusion 
with saline. Brains were fixed in 4% formaldehyde and coronal slices (100 μm) were made 
for Cresyl violet staining.
3H-Glutamate uptake
Sodium-dependent and sodium-independent uptake activity was measured using an in vitro 
slice preparation as described previously (Knackstedt et al. 2010). Briefly, drug-naïve rats 
were decapitated and bilateral punches of the nucleus accumbens core were dissected and 
sliced into 250 × 250 μm sections using a McIllwan tissue chopper (St. Louis, MO, USA). 
Slices were incubated at 37°C in either oxygenated Krebs-Ringer’s solution phosphate 
buffer (140 mM NaCl, 1.3 mM CaCl2, 1.2 mM KH2PO4, 5 mM HEPES, 10 mM glucose 
and 1 mM MgCl2, pH 7.4) to quantify sodium-dependent uptake, or an identical buffer in 
which NaCl was replaced with 140 mM choline chloride to measure sodium-independent 
uptake. Uptake was stimulated by the addition of L-[3H] glutamate (150 nM, 51 Ci/mM; 
Perkin-Elmer, Boston, MA, USA) to slices in the presence of 10 μM L-glutamate. This 
concentration was chosen based on our previous findings that uptake at this concentration is 
significantly decreased following cocaine self-administration (Knackstedt et al. 2010). The 
uptake reaction was conducted at 37°C for 15 minutes and then terminated by washing the 
slices in ice-cold, sodium-free Krebs-Ringers buffer. Slices were solubilized at room 
temperature with 1% sodium dodecyl sulfate (SDS) and the level of radioactivity determined 
using a liquid scintillation counter. Protein content was measured using a bicinchoninic acid 
assay protein assay (Thermo Scientific, Rockford, IL, USA) and the cpm/mg protein 
calculated.
Western blotting
For Western analysis, a membrane subfraction was performed as described previously 
(Reissner et al. 2011). All protein buffers were supplemented 1:100 with Halt protease and 
phosphatase inhibitors, including ethylene-diaminetetraacetic acid (Thermo Scientific, 
Rockford, IL, USA). Membrane pellet was resuspended in 30 μl 1× RIPA buffer (Thermo 
Scientific) plus 1.0% SDS and inhibitors. Equal microgram quantities were loaded per lane 
on a 10% Criterion Bis-Tris gel (Bio-Rad, Hercules, CA, USA). Following electrophoresis, 
proteins were transferred for 7 minutes on an iblot transfer apparatus (Life Technologies, 
Carlsbad, CA, USA), and blocking was performed for 1 hour at room temperature in 3.0% 
non-fat dry milk in tris buffered saline plus 0.1% tween-20. Primary antibodies against 
GLT-1 (Abcam, ab41621, 1:500; Cambridge, MA, USA), calnexin (Enzo Life Sciences, 
ADI-SPA-860, 1:1000; Farmingdale, NY, USA) were incubated overnight at 4°C. Samples 
were heated at 37°C for 30 minutes prior to electrophoresis.
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Glutamate uptake was evaluated using a Student’s t-test, reinstatement data using a three-
way ANOVA and Western blotting using a one-way ANOVA. For post hoc multiple 
comparisons either a Dunnett’s test or a Bonferroni t-test were used.
RESULTS
Cocaine self-administration reduces both cystine-glutamate exchange and glutamate 
transport via GLT-1 in the nucleus accumbens (Baker et al. 2003; Sari et al. 2009; 
Knackstedt et al. 2010). We employed an antisense vivo-morpholino strategy to evaluate the 
role played by each protein in cue-induced reinstatement of cocaine seeking (Reissner et al. 
2012). Figure 1a shows the treatment protocol used. Active lever pressing during self-
administration and extinction training, as well as average number of cocaine infusions taken 
during self-administration, were statistically equivalent between animals assigned to the 
saline versus NAC groups (not shown). A three-way ANOVA revealed a significant 
interaction between oligomer, i.p. treatment and time (F(1,100) = 9.389, P = 0.003, Fig. 1). 
This was followed-up with a two-way ANOVA to analyze lever pressing during the last day 
of extinction, which revealed no effect of oligomer or i.p. treatment, nor any interaction. A 
subsequent two-way ANOVA to analyze reinstatement between groups indicated a 
significant interaction between oligomer and i.p. treatment (interaction F(1,100) = 9.078, P = .
003). Figure 1b shows that reinstatement was reduced by NAC treatment in animals treated 
with control sequence, even though the last NAC injection was administered 24 hours before 
the reinstatement session. Similarly, NAC reduced reinstatement in animals pre-treated with 
xCT vivo-morpholino antisense to inhibit the cystine-glutamate exchanger. In contrast, NAC 
treatment in animals administered antisense vivo-morpholino targeted to GLT-1 mRNA 
showed a marked potentiation of reinstated behavior. Importantly, treatment with antisense 
morpholino targeting either xCT or GLT-1 did not alter cue-induced reinstatement among 
rats treated with daily saline rather than NAC prior to reinstatement testing. Figure 1c shows 
the location of the tip of all microinjection cannula determined from Cresyl violet stained 
coronal sections, into the nucleus accumbens core.
The capacity of antisense vivo-morpholinos to reduce protein expression of GLT-1 and xCT 
has been previously reported (Reissner et al. 2012). However, because of the surprising lack 
of effect of xCT antisense on the behavioral effect of NAC, we sought to extend this finding 
to confirm that xCT antisense morpholinos functionally impair the cystine-glutamate 
exchanger. The effect of xCT antisense vivo-morpholino was quantified by measuring Na+-
dependent and -independent glutamate uptake 3H-glutamate in accumbens tissue slices 
(Bridges et al. 2012). Figure 2a shows that compared with the xCT control sequence, xCT 
antisense vivo-morpholino microinjections significantly reduced Na+-independent 3H-
glutamate uptake by 23 percent (t(10) = 3.05, P = 0.012), but did not affect Na+-dependent 
uptake that characterizes transport through glutamate transporters, predominantly GLT-1 
(Danbolt 2001). This reduction in Na+-independent uptake is in agreement with the 25 
percent reduction in xCT protein expression previously reported using the same xCT vivo-
morpholino antisense approach (Reissner et al. 2012), and confirms functional suppression 
by the xCT antisense, with lack of effect on GLT-1. It is worthwhile to note that while 
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modest, this degree of suppression is also similar to the reported effect of cocaine self-
administration and extinction on xCT protein expression in the accumbens (Knackstedt et al. 
2010).
Because reinstatement was so markedly affected by treatment with GLT-1 antisense plus 
NAC (Fig. 1b), we also examined membrane content of GLT-1 protein after both GLT-1 
antisense vivo-morpholino and NAC. Figure 2b shows that cocaine-experienced animals 
treated with control vivo-morpholino had reduced GLT-1 compared with yoked-saline 
control oligomer-treated saline animals, and that cocaine-reduced GLT-1 levels were 
restored by NAC treatment (black bar) (F(3,27) = 5.04, P = 0.007). However, the capacity of 
NAC to elevate GLT-1 was abolished by treating the accumbens with GLT-1 antisense vivo-
morpholino (hatched bar).
The augmented cue-induced reinstatement following antisense vivo-morpholino suppression 
of GLT-1 when combined with NAC was surprising. NAC is known to elevate the basal 
levels of glutamate by stimulating the efflux of glutamate through the cystine-glutamate 
exchanger, and this is augmented by the reduced glutamate uptake produced by reduced 
GLT-1 activity (Baker et al. 2003; Melendez, Vuthiganon & Kalivas 2005). Increased 
extracellular glutamate concentrations would thus have access to extrasynaptic glutamate 
receptors, including mGluR5, that strongly regulate cocaine reinstatement; stimulation 
potentiates while antagonism of mGluR5 inhibits reinstatement (Kumaresan et al. 2009; 
Martin-Fardon et al. 2009; Wang et al. 2013). Together, these data pose a hypothesis that 
concomitant increased extracellular glutamate via xc− and suppression of uptake leads to 
increased stimulation of mGluR5 which accounts for the potentiated reinstatement seen in 
animals treated with NAC plus GLT-1 antisense vivo-morpholino. To test this hypothesis, 
we paired a sub-threshold dose of mGluR5 negative allosteric modulator MTEP with GLT-1 
antisense in the accumbens and systemic NAC treatment. Figure 3a shows that 
administration of a dose of MTEP (0.5 mg/kg, i.p.) that is sub-threshold for inhibiting 
reinstatement in animals treated with GLT-1 antisense plus saline, abolished the potentiated 
reinstatement produced in rats treated with GLT-1 antisense plus NAC (NAC versus saline 
F(1,55) = 6.88, P = 0.011; MTEP versus saline F(1,55) = 7.49, P = 0.008; interaction was not 
significant).
DISCUSSION
Our data indicate that restored expression of GLT-1, but not xCT, is critically important for 
the ability of NAC to suppress cue-primed reinstatement of cocaine seeking. Indeed, 
preventing the restoration of GLT-1 by NAC actually potentiated cue-induced reinstatement. 
The down-regulation of GLT-1 by antisense vivo-morpholino would be expected to reduce 
the elimination of extracellular glutamate and thereby increase extracellular levels of 
glutamate, akin to what occurs when GLT-1 is pharmacologically inhibited (Danbolt 2001). 
This increase would likely be exacerbated by NAC, which increases glutamate release by 
activating cystine-glutamate exchange (Baker et al. 2003; Moran et al. 2005; Bridges et al. 
2012). The potential accumulation of glutamate in the extracellular space could result in the 
stimulation of extrasynaptic glutamate receptors, including mGluR5. Pharmacological 
activation of mGluR5 in the accumbens promotes cocaine reinstatement (Moussawi et al. 
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2009; Wang et al. 2013), while inhibiting mGluR5 prevents reinstated cocaine seeking 
(Backstrom & Hyytia 2007; Kumaresan et al. 2009; Wang et al. 2013). Accordingly, we 
found that the augmented reinstatement in NAC-treated animals produced by pre-treatment 
with GLT-1 antisense vivo-morpholino was prevented by administration of a negative 
allosteric modulator of mGluR5, MTEP.
How NAC increases GLT-1 and cystine-glutamate exchange is unclear. It was previously 
assumed that NAC was deacetylated, then dimerized to form cystine in the extracellular 
space and act as a substrate to drive cystine-glutamate exchange (Flanagan & Meredith 
1991). However, it was recently shown that NAC enters cells primarily via cysteine 
transporters (Kupchik et al. 2012). Moreover, in tissue slices, high concentrations of NAC 
provoke glutamate release via cystine-glutamate exchange that potentiates excitatory 
postsynaptic currents (EPSCs) in accumbens medium spiny cells. This potentiation is 
blocked by MTEP (Kupchik et al. 2012); thereby, providing a mechanistic link between 
NAC and mGluR5 stimulation that could mediate the potentiated reinstatement in rats 
treated with the combination of GLT-1 antisense vivo-morpholino and NAC.
A decrease in expression of GLT-1 in the accumbens is one of the most consistent findings 
across drugs of abuse and administration protocols found following self-administration of 
cocaine, heroin, alcohol and nicotine (Knackstedt et al. 2010; Fischer-Smith, Houston & 
Rebec 2012; Sari & Sreemantula 2012; Gipson et al. 2013). In addition, restored GLT-1 
levels are observed following daily treatment with either NAC or ceftriaxone, two 
compounds that suppress reinstated cocaine, nicotine, alcohol, food and/or heroin seeking 
(Zhou & Kalivas 2007; Sari et al. 2009, 2011; Knackstedt et al. 2010; Moussawi et al. 2011; 
Ramirez-Nino, D’Souza & Markou 2013). NAC and ceftriaxone also restore cystine-
glutamate exchange in rats trained to self-administer cocaine (Trantham-Davidson et al. 
2012). While we show that this latter action is not critical for inhibiting cocaine 
reinstatement, these data appear contrary to the assertions we and others have made 
regarding a pivotal role for cystine-glutamate exchange in reinstated drug seeking (Kalivas 
2009; Bridges et al. 2012). However, it is important to distinguish studies that employ a 
single, acute NAC pre-treatment prior to reinstating cocaine seeking and studies such as ours 
that use daily NAC and test animals in the absence of an acute NAC pre-treatment. The 
inhibition of cocaine reinstatement by NAC has been directly linked to activation of cystine-
glutamate exchange to promote the release of non-synaptic glutamate, and thereby stimulate 
presynaptic mGluR2/3 to reduce synaptic glutamate release probability (Kalivas 2009). 
Supporting this mechanism, intra-accumbens inhibition of either cystine-glutamate exchange 
or mGluR2/3 blocks the ability of acute NAC to reduce cocaine reinstatement (Moran et al. 
2005; Kau et al. 2008). In addition, although higher concentrations of NAC (50 μM) acutely 
applied to accumbens tissue slices promote EPSC amplitude via mGluR5 stimulation (see 
above), at lower concentrations (0.5 μM), NAC elicits an mGluR2/3-dependent inhibition of 
EPSCs, supporting the capacity of acute NAC to act via stimulating mGluR2/3 (Kupchik et 
al. 2012). Thus, NAC would appear to regulate cocaine reinstatement acutely by increasing 
cystine-glutamate exchange and indirectly activating mGluR2/3; however, it is the 
restoration of GLT-1 that is most critical for producing the more enduring protection from 
cocaine reinstatement elicited by chronic NAC treatment.
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Results presented here support a critical role for drug-induced downregulation of accumbens 
GLT-1 in the vulnerability to relapse, and that the restoration of GLT-1 by daily NAC 
treatments is a critical mechanism whereby NAC inhibits reinstated cocaine seeking. 
Importantly, while a number of studies demonstrate pre-clinical and clinical efficacy of 
NAC against cocaine seeking, results are not unilaterally positive (Mardikian et al. 2007; 
Berk et al. 2013). For example, in a recent double-blind placebo-controlled study of NAC 
for cocaine dependence over 8 weeks for outpatient, treatment-seeking users, overall use 
was not statistically different between groups (LaRowe et al. 2013). Importantly, however, a 
significant difference was found between subjects receiving NAC versus placebo control for 
subjects abstinent from cocaine at the outset of the study. This group may be considered 
analogous to the experimental design described in the current study, in which NAC is given 
prior to the last 5 days of the extinction training phase, hence providing a candidate cellular 
mechanism for the observed clinical effect. Given that a consequence of downregulated 
GLT-1 is increased spillover of synaptically released glutamate onto extracellular glutamate 
receptors (Bergles, Diamond & Jahr 1999), these data support a strategy for treating cocaine 
addiction that may involve not only refining drug treatments that promote GLT-1, but also 
treatments that inhibit extrasynaptic glutamate receptors such as mGluR5.
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Vivo-morpholino antisense inhibition of GLT-1, not xCT prevented N-acetylcysteine 
inhibition of cue-induced reinstatement of cocaine seeking. (a) Treatment protocol for all 
experiments showing the self-administration of cocaine or yoked-saline, followed by 
extinction and daily morpholino and NAC or saline administration that was completed 24 
hours prior to either a conducting a cue-induced reinstatement session or obtaining nucleus 
accumbens tissue. (b) Active lever pressing during cue-induced reinstatement (120 minutes 
sessions) in rats extinguished from cocaine self-administration. AS-antisense vivo-
morpholino, Control refers to the combined GLT-1 and xCT control sequence vivo-
morpholino (Reissner et al. 2012). N is shown in bars. (c) Histologically determined 
location of vivo-morpholino microinjections, largely localized to the core subcompartment 
of the nucleus accumbens
*P < 0.05, comparing all treatment groups to Saline-Control using a two-way ANOVA 
followed by a Dunnett’s post hoc.
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Vivo-morpholino reduced xCT function and GLT-1 membrane content. (a) Rats treated into 
the accumbens with xCT vivo-morpholino antisense (AS) had reduced Na+-independent 3H-
glutamate uptake in accumbens tissue slices. (b) Treatment with GLT-1 vivo-morpholino 
AS reversed NAC-induced restoration of GLT-1 protein levels in the accumbens of rats 
trained to self-administer cocaine versus yoked-saline controls. N is shown in bars. Abcissa 
indicates i.v. administration group (saline or cocaine). Vivo-morpholino group and saline 
versus NAC treatment is indicated in the legend
*P < 0.05 compared with yoked saline using a one-way ANOVA followed by a Dunnett’s 
post hoc comparison.
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Inhibiting mGluR5 prevented the augmented reinstatement elicited by NAC treatment in rats 
pre-treated with GLT-1 vivo-morpholino antisense.The same protocol outlined in Fig. 1a 
was used. All animals were treated with GLT-1 vivo-morpholino anti-sense, followed by 
either NAC or saline, followed by an acute administration of MTEP (0.5 mg/kg, ip) or saline 
(ip), 10 minutes prior to initiating cue-induced reinstatement
*P < 0.05, comparing NAC + saline to Saline + Saline using a Student’s t-test followed by a 
Bonferroni adjustment for multiple comparisons.
+ P < 0.05, comparing NAC + saline to NAC + MTEP.
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